» Articles » PMID: 35571385

A Case Report and Literature Review: Diagnosis and Treatment of Human Immunodeficiency Virus Coinfected with Visceral Leishmania by Metagenomic Next-generation Sequencing in China

Overview
Journal Ann Transl Med
Date 2022 May 16
PMID 35571385
Authors
Affiliations
Soon will be listed here.
Abstract

Background: human immunodeficiency virus (HIV) can disrupt the body's immune system, increasing the chance of various opportunistic infections. The risk of misdiagnosis and underdiagnosis is high for HIV and coinfection. Visceral leishmaniasis (VL) has become a significant opportunistic infection in HIV type 1 (HIV-1)-infected patients in the epidemic region. Co-infection is difficult to diagnose, especially in non-endemic areas.

Case Description: This study presents a case of VL in a middle-aged male patient with HIV coinfection, where the diagnosis was circuitous and complex. The patient was a 44-year-old male who was hospitalized due to fever. We considered common pathogen infection or hemophagocytic syndrome, so we did various etiological examinations and bone marrow biopsy smears, but no positive pathogens were found. Then we used a variety of empirical treatment, but the patient's temperature did not drop significantly. After the final diagnosis of VL using metagenomic next-generation sequencing (mNGS), we read the bone marrow smear and biopsy specimens again, and ultimately the Leishman-Donovan body and tissue intracellular pathogens were found. The patient responded well to treatment with sodium stibogluconate (SSG), his temperature gradually recovered from hyperthermia to normal, liver and spleen size gradually decreased, hemoglobin and platelet count rebounded, and weight increased by 1.5 kg after discharge from the hospital. We hope to deepen clinicians' understanding of mNGS for VL diagnosis and provide a review of the literature.

Conclusions: For patients with HIV coinfection, mNGS-a test that can detect multiple pathogens simultaneously-can be used routinely when multiple pathogen tests showed no positive results, multiple empiric anti-infective therapies failed, and hospital technology and the patient's economy are adequate. While giving highly active antiretroviral therapy (HAART), liposomal amphotericin B (L-AMB) is highly recommended because of its better efficacy and lower side effects. Not only is the treatment of leishmaniasis critical but also follow-up at a later stage is essential. After discharged, the patient had no significant discomfort and no increase in body temperature, his hemoglobin and platelets increased further. He demonstrated a further reduction in liver and spleen size and a weight gain of 1.5 kg.

Citing Articles

Metagenomic next-generation sequencing assists in the diagnosis of visceral leishmaniasis in non-endemic areas of China.

Zhao R, He G, Xiang L, Ji M, He R, Wei X Front Cell Infect Microbiol. 2025; 15:1517046.

PMID: 39981377 PMC: 11839618. DOI: 10.3389/fcimb.2025.1517046.


Diagnosis of human angiostrongyliasis in a case of hydrocephalus using next-generation sequencing: a case report and literature review.

Liu D, Li N, Zhu Y, Chen Q, Fan X, Feng J BMC Neurol. 2024; 24(1):281.

PMID: 39134956 PMC: 11318341. DOI: 10.1186/s12883-024-03663-7.


Application of metagenomic next-generation sequencing technology in the etiological diagnosis of peritoneal dialysis-associated peritonitis.

Guo S, Fu G, Hu Y, Liu J, Wang Y Open Life Sci. 2024; 19(1):20220865.

PMID: 38681728 PMC: 11049737. DOI: 10.1515/biol-2022-0865.


The application of metagenomic next-generation sequencing in pathogen diagnosis: a bibliometric analysis based on Web of Science.

He S, Wei J, Feng J, Liu D, Wang N, Chen L Front Cell Infect Microbiol. 2023; 13:1112229.

PMID: 37600953 PMC: 10434771. DOI: 10.3389/fcimb.2023.1112229.

References
1.
Desjeux P . The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg. 2001; 95(3):239-43. DOI: 10.1016/s0035-9203(01)90223-8. View

2.
De La Loma A, Alvar J, Martinez Galiano E, Blazquez J, Alcala Munoz A, Najera R . Leishmaniasis or AIDS?. Trans R Soc Trop Med Hyg. 1985; 79(3):421-2. DOI: 10.1016/0035-9203(85)90400-6. View

3.
Cruz I, Morales M, Noguer I, Rodriguez A, Alvar J . Leishmania in discarded syringes from intravenous drug users. Lancet. 2002; 359(9312):1124-5. DOI: 10.1016/s0140-6736(02)08160-6. View

4.
Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson R . Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis. 2006; 43(7):917-24. DOI: 10.1086/507530. View

5.
Lun Z, Wu M, Chen Y, Wang J, Zhou X, Liao L . Visceral Leishmaniasis in China: an Endemic Disease under Control. Clin Microbiol Rev. 2015; 28(4):987-1004. PMC: 4575399. DOI: 10.1128/CMR.00080-14. View